{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:31:12Z","timestamp":1793410272195,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA222959"],"award-info":[{"award-number":["R01CA222959"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA193880"],"award-info":[{"award-number":["R01CA193880"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5 P01 CA190174"],"award-info":[{"award-number":["5 P01 CA190174"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R03CA230573"],"award-info":[{"award-number":["R03CA230573"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"Emerson Collective Cancer Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunosuppressive tumor microenvironment (TME) and ascites-derived spheroids in ovarian cancer (OC) facilitate tumor growth and progression, and\u00a0also pose major obstacles for cancer therapy. The molecular pathways involved in the OC-TME interactions, how the crosstalk impinges on OC aggression and chemoresistance are not well-characterized. Here, we demonstrate that tumor-derived UBR5, an E3 ligase overexpressed in human OC associated with poor prognosis, is essential for OC progression principally by promoting tumor-associated macrophage recruitment and activation via key chemokines and cytokines. UBR5 is also required to sustain cell-intrinsic \u03b2-catenin-mediated signaling to promote cellular adhesion\/colonization and organoid formation by controlling the p53 protein level. OC-specific targeting of UBR5 strongly augments the survival benefit of conventional chemotherapy and immunotherapies. This work provides mechanistic insights into the novel oncogene-like functions of UBR5 in regulating the OC-TME crosstalk and suggests that UBR5 is a potential therapeutic target in OC treatment for modulating the TME and cancer stemness.<\/jats:p>","DOI":"10.1038\/s41467-020-20140-0","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T11:04:42Z","timestamp":1607425482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":153,"title":["Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages"],"prefix":"10.1038","volume":"11","author":[{"given":"Mei","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladapo O.","family":"Yeku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3065","authenticated-orcid":false,"given":"Sarwish","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Purdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-918X","authenticated-orcid":false,"given":"Tuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-4352","authenticated-orcid":false,"given":"Junhua","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1383-0535","authenticated-orcid":false,"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-5388","authenticated-orcid":false,"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-1840","authenticated-orcid":false,"given":"Xiaojing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"20140_CR1","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.21037\/tcr.2017.02.01","volume":"6","author":"ST Eblen","year":"2017","unstructured":"Eblen, S. T. & Bradley, A. MOAP-1, UBR5 and cisplatin resistance in ovarian cancer. Transl. Cancer Res. 6, S18\u2013S21 (2017).","journal-title":"Transl. Cancer Res."},{"key":"20140_CR2","first-page":"937","volume":"93","author":"CA Doubeni","year":"2016","unstructured":"Doubeni, C. A., Doubeni, A. R. & Myers, A. E. Diagnosis and management of ovarian cancer. Am. Fam. Phys. 93, 937\u2013944 (2016).","journal-title":"Am. Fam. Phys."},{"key":"20140_CR3","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3802\/jgo.2018.29.e32","volume":"29","author":"SS Li","year":"2018","unstructured":"Li, S. S., Ma, J. & Wong, A. S. T. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism. J. Gynecol. Oncol. 29, e32 (2018).","journal-title":"J. Gynecol. Oncol."},{"key":"20140_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","volume":"113","author":"K Shield","year":"2009","unstructured":"Shield, K., Ackland, M. L., Ahmed, N. & Rice, G. E. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol. Oncol. 113, 143\u2013148 (2009).","journal-title":"Gynecol. Oncol."},{"key":"20140_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-9-99","volume":"9","author":"S L\u2019Esperance","year":"2008","unstructured":"L\u2019Esperance, S., Bachvarova, M., Tetu, B., Mes-Masson, A. M. & Bachvarov, D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 9, 99 (2008).","journal-title":"BMC Genomics"},{"key":"20140_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","volume":"7","author":"DS Tan","year":"2006","unstructured":"Tan, D. S., Agarwal, R. & Kaye, S. B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7, 925\u2013934 (2006).","journal-title":"Lancet Oncol."},{"key":"20140_CR7","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.7150\/jca.20314","volume":"8","author":"DL Cai","year":"2017","unstructured":"Cai, D. L. & Jin, L. P. Immune cell population in ovarian tumor microenvironment. J. Cancer 8, 2915\u20132923 (2017).","journal-title":"J. Cancer"},{"key":"20140_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fonc.2014.00137","volume":"4","author":"EK Colvin","year":"2014","unstructured":"Colvin, E. K. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front. Oncol. 4, 137 (2014).","journal-title":"Front. Oncol."},{"key":"20140_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2017.00024","volume":"7","author":"T Worzfeld","year":"2017","unstructured":"Worzfeld, T. et al. The unique molecular and cellular microenvironment of ovarian cancer. Front. Oncol. 7, 24 (2017).","journal-title":"Front. Oncol."},{"key":"20140_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ijc.28335","volume":"134","author":"S Reinartz","year":"2014","unstructured":"Reinartz, S. et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int. J. Cancer 134, 32\u201342 (2014).","journal-title":"Int. J. Cancer"},{"key":"20140_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","volume":"147","author":"X Yuan","year":"2017","unstructured":"Yuan, X. et al. Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis. Gynecol. Oncol. 147, 181\u2013187 (2017).","journal-title":"Gynecol. Oncol."},{"key":"20140_CR12","doi-asserted-by":"publisher","first-page":"e0157079","DOI":"10.1371\/journal.pone.0157079","volume":"11","author":"E Kinsella","year":"2016","unstructured":"Kinsella, E. et al. Use of a conditional Ubr5 mutant allele to investigate the role of an N-end rule ubiquitin-protein ligase in Hedgehog signalling and embryonic limb development. PLoS ONE 11, e0157079 (2016).","journal-title":"PLoS ONE"},{"key":"20140_CR13","doi-asserted-by":"publisher","first-page":"7225","DOI":"10.1128\/MCB.24.16.7225-7234.2004","volume":"24","author":"DN Saunders","year":"2004","unstructured":"Saunders, D. N. et al. Edd, the murine hyperplastic disc gene, is essential for yolk sac vascularization and chorioallantoic fusion. Mol. Cell Biol. 24, 7225\u20137234 (2004).","journal-title":"Mol. Cell Biol."},{"key":"20140_CR14","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1038\/sj.onc.1206775","volume":"22","author":"JL Clancy","year":"2003","unstructured":"Clancy, J. L. et al. EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene 22, 5070\u20135081 (2003).","journal-title":"Oncogene"},{"key":"20140_CR15","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/0008-5472.CAN-16-2409","volume":"77","author":"L Liao","year":"2017","unstructured":"Liao, L. et al. E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple-negative breast cancer. Cancer Res. 77, 2090\u20132101 (2017).","journal-title":"Cancer Res."},{"key":"20140_CR16","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/carcin\/bgt489","volume":"35","author":"A Bradley","year":"2014","unstructured":"Bradley, A. et al. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis 35, 1100\u20131109 (2014).","journal-title":"Carcinogenesis"},{"key":"20140_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/sj.bjc.6604281","volume":"98","author":"PM O\u2019Brien","year":"2008","unstructured":"O\u2019Brien, P. M. et al. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br. J. Cancer 98, 1085\u20131093 (2008).","journal-title":"Br. J. Cancer"},{"key":"20140_CR18","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/onc.2016.336","volume":"36","author":"K Matsuura","year":"2017","unstructured":"Matsuura, K., Huang, N. J., Cocce, K., Zhang, L. & Kornbluth, S. Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. Oncogene 36, 1698\u20131706 (2017).","journal-title":"Oncogene"},{"key":"20140_CR19","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1158\/1541-7786.MCR-15-0383","volume":"13","author":"RF Shearer","year":"2015","unstructured":"Shearer, R. F., Iconomou, M., Watts, C. K. & Saunders, D. N. Functional roles of the E3 ubiquitin ligase UBR5 in cancer. Mol. Cancer Res. 13, 1523\u20131532 (2015).","journal-title":"Mol. Cancer Res."},{"key":"20140_CR20","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446 (2015).","journal-title":"Oncoimmunology"},{"key":"20140_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"20140_CR22","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostatsis. Cell 161, 1527\u20131538 (2015).","journal-title":"Cell"},{"key":"20140_CR23","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1172\/JCI87252","volume":"126","author":"M Yin","year":"2016","unstructured":"Yin, M. et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J. Clin. Investig. 126, 4157\u20134173 (2016).","journal-title":"J. Clin. Investig."},{"key":"20140_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood-2013-01-480749","volume":"122","author":"S Jacquelin","year":"2013","unstructured":"Jacquelin, S. et al. CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice. Blood 122, 674\u2013683 (2013).","journal-title":"Blood"},{"key":"20140_CR25","doi-asserted-by":"publisher","first-page":"14972","DOI":"10.1074\/jbc.M110.182527","volume":"286","author":"S Ling","year":"2011","unstructured":"Ling, S. & Lin, W. C. EDD inhibits ATM-mediated phosphorylation of p53. J. Biol. Chem. 286, 14972\u201314982 (2011).","journal-title":"J. Biol. Chem."},{"key":"20140_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4161\/cc.11.4.19154","volume":"11","author":"VA Smits","year":"2012","unstructured":"Smits, V. A. EDD induces cell cycle arrest by increasing p53 levels. Cell Cycle 11, 715\u2013720 (2012).","journal-title":"Cell Cycle"},{"key":"20140_CR27","doi-asserted-by":"publisher","unstructured":"Ignatius, M. S. et al. tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. Elife https:\/\/doi.org\/10.7554\/eLife.37202 (2018).","DOI":"10.7554\/eLife.37202"},{"key":"20140_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.scr.2018.01.035","volume":"27","author":"R Zhou","year":"2018","unstructured":"Zhou, R. et al. A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing. Stem Cell Res. 27, 131\u2013135 (2018).","journal-title":"Stem Cell Res."},{"key":"20140_CR29","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1158\/1541-7786.MCR-18-1195","volume":"17","author":"S Watanabe","year":"2019","unstructured":"Watanabe, S. et al. TP53 mutation by CRISPR system enhances the malignant potential of colon cancer. Mol. Cancer Res. 17, 1459\u20131467 (2019).","journal-title":"Mol. Cancer Res."},{"key":"20140_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"N Cancer Genome Atlas Research","year":"2011","unstructured":"Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"20140_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967\u2013974 (2005).","journal-title":"Nature"},{"key":"20140_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ijc.11086","volume":"106","author":"IS Patel","year":"2003","unstructured":"Patel, I. S., Madan, P., Getsios, S., Bertrand, M. A. & MacCalman, C. D. Cadherin switching in ovarian cancer progression. Int. J. Cancer 106, 172\u2013177 (2003).","journal-title":"Int. J. Cancer"},{"key":"20140_CR33","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.18632\/oncotarget.6588","volume":"7","author":"PW Choi","year":"2016","unstructured":"Choi, P. W. et al. Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation and collective cell movement in ovarian cancer cells. Oncotarget 7, 4110\u20134121 (2016).","journal-title":"Oncotarget"},{"key":"20140_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1242\/jcs.000455","volume":"121","author":"MJ Wheelock","year":"2008","unstructured":"Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y. & Johnson, K. R. Cadherin switching. J. Cell Sci. 121, 727\u2013735 (2008).","journal-title":"J. Cell Sci."},{"key":"20140_CR35","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/onc.2014.178","volume":"34","author":"S Condello","year":"2015","unstructured":"Condello, S. et al. beta-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene 34, 2297\u20132308 (2015).","journal-title":"Oncogene"},{"key":"20140_CR36","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1158\/0008-5472.CAN-16-1115","volume":"77","author":"MW Chen","year":"2017","unstructured":"Chen, M. W. et al. The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res. 77, 1955\u20131967 (2017).","journal-title":"Cancer Res."},{"key":"20140_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/ijc.21291","volume":"118","author":"M Mestdagt","year":"2006","unstructured":"Mestdagt, M. et al. Transactivation of MCP-1\/CCL2 by beta-catenin\/TCF-4 in human breast cancer cells. Int. J. Cancer 118, 35\u201342 (2006).","journal-title":"Int. J. Cancer"},{"key":"20140_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ygyno.2013.09.034","volume":"131","author":"RC Arend","year":"2013","unstructured":"Arend, R. C., Londono-Joshi, A. I., Straughn, J. M. Jr. & Buchsbaum, D. J. The Wnt\/beta-catenin pathway in ovarian cancer: a review. Gynecol. Oncol. 131, 772\u2013779 (2013).","journal-title":"Gynecol. Oncol."},{"key":"20140_CR39","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ijc.24188","volume":"124","author":"KL Sodek","year":"2009","unstructured":"Sodek, K. L., Ringuette, M. J. & Brown, T. J. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int. J. Cancer 124, 2060\u20132070 (2009).","journal-title":"Int. J. Cancer"},{"key":"20140_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru, M., O\u2019Cearbhaill, R., Pendharkar, S., Spriggs, D. R. & Brentjens, R. J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015).","journal-title":"J. Transl. Med."},{"key":"20140_CR41","doi-asserted-by":"publisher","first-page":"26468","DOI":"10.1074\/jbc.M203527200","volume":"277","author":"MJ Henderson","year":"2002","unstructured":"Henderson, M. J. et al. EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response. J. Biol. Chem. 277, 26468\u201326478 (2002).","journal-title":"J. Biol. Chem."},{"key":"20140_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccr.2011.01.005","volume":"19","author":"Y Huang","year":"2011","unstructured":"Huang, Y., Snuderl, M. & Jain, R. K. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 19, 1\u20132 (2011).","journal-title":"Cancer Cell"},{"key":"20140_CR43","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1038\/onc.2017.185","volume":"36","author":"SKY To","year":"2017","unstructured":"To, S. K. Y. et al. beta-catenin downregulates Dicer to promote ovarian cancer metastasis. Oncogene 36, 5927\u20135938 (2017).","journal-title":"Oncogene"},{"key":"20140_CR44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1091\/mbc.e10-05-0440","volume":"22","author":"A Hay-Koren","year":"2011","unstructured":"Hay-Koren, A., Caspi, M., Zilberberg, A. & Rosin-Arbesfeld, R. The EDD E3 ubiquitin ligase ubiquitinates and up-regulates beta-catenin. Mol. Biol. Cell 22, 399\u2013411 (2011).","journal-title":"Mol. Biol. Cell"},{"key":"20140_CR45","doi-asserted-by":"publisher","first-page":"E943","DOI":"10.1073\/pnas.1100132108","volume":"108","author":"N Dompe","year":"2011","unstructured":"Dompe, N. et al. A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis. Proc. Natl Acad. Sci. USA 108, E943\u2013951 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"20140_CR46","doi-asserted-by":"publisher","unstructured":"Saez, I. et al. The E3 ubiquitin ligase UBR5 interacts with the H\/ACA ribonucleoprotein complex and regulates ribosomal RNA biogenesis in embryonic stem cells. FEBS Lett. https:\/\/doi.org\/10.1002\/1873-3468.13559 (2019).","DOI":"10.1002\/1873-3468.13559"},{"key":"20140_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrc.2017.105","volume":"18","author":"D Senft","year":"2018","unstructured":"Senft, D., Qi, J. & Ronai, Z. A. Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat. Rev. Cancer 18, 69\u201388 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"20140_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","volume":"3","author":"SL Gaillard","year":"2016","unstructured":"Gaillard, S. L., Secord, A. A. & Monk, B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol. Oncol. Res Pr. 3, 11 (2016).","journal-title":"Gynecol. Oncol. Res Pr."},{"key":"20140_CR49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847\u2013856 (2018).","journal-title":"Nat. Biotechnol."},{"key":"20140_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2014.04.057","volume":"187","author":"J Mai","year":"2014","unstructured":"Mai, J. et al. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. J. Control Release 187, 22\u201329 (2014).","journal-title":"J. Control Release"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20140-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20140-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20140-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:19:13Z","timestamp":1670293153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20140-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["20140"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-20140-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]},"assertion":[{"value":"3 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6298"}}